The standardization of a biochemical laboratory
determination of multiple myeloma
Maisnar V.1,2, Tichý M.2,3, Hájek R.2,4, Friedecký B.3, Jarolímková E.6, Vogtová D.7, Kouřil F.8, Ženková J.9, Vávrová J.3, Novotná H.5, Benáková H.6, Hachová L.6, Kopřivová H.7, Zábranská A.8, Slabý P.9, Palička V.3, Čermáková Z.5, Bezdíčková D.6, Čechák P.7
1II. interní klinika – Oddělení klinické hematologie, LF UK a FN, Hradec Králové, 2Česká myelomová skupina, 3Ústav klinické biochemie a diagnostiky LF UK a FN, Hradec Králové, 4Interní hematoonkologická klinika FN a LF MU, Brno – Bohunice, 5Oddělení klinické biochemie a hematologie FN, Brno – Bohunice, 6Ústav klinické biochemie a laboratorní diagnostiky, VFN Praha, 7Ústav biochemie a pathobiochemie, FN-KV, Praha, 8Oddělení klinické biochemie, FN Olomouc, 9Ústav klinické biochemie a hematologie LF UK a FN Plzeň. |
|
Summary:
Objective: The standardization of the biochemical measurement procedures in a blood serum of patients with multiple
myeloma concerning an implementation of a new international prognostic index, which uses only two laboratory
markers, albumin and beta-2 microglobulin. Design: The study compares results of albumin, beta-2 microglobulin
and partly the concentration of paraproteins from six cooperative centers, which provide treatment of
the multiple myeloma in the Czech Republic in order to integrate these investigations. Material and Methods: The
laboratories of university hospitals – General University Hospital of Prague, University Hospital of Prague –
Vinohrady, Hradec Králové, Olomouc, Brno – Bohunice and Plzeň have been chosen for the implementation of
the study. Each control serum sample was divided into six same parts and was frozen at -80 °C. The transportation
of the samples to the single laboratory was performed in a frozen box and the samples were stored at least at
-70 °C till the date of determination. The whole project lasted two years and step by step it was divided into three
periods (2003–2005). In the first period the determination of albumin was standardized and the unsuitability of
the RIA method determination of beta-2 microglobulin with other methods was proofed. In the second period the
determination of beta-2 microglobulin was standardized successfully, but because of some technical defects it was
not possible to use the samples for the determination of paraproteins concentration. In the third period of the
study 12 samples of blood serums were distributed, always with one monoclonal immunoglobulin to determine its
concentration. Results: The determination of albumin is well standardized, a confidence interval for 95% is between
5.9–6.1% (tolerance limit for external quality assessments up to 9%). The unification of methods managed a comparability of the results of beta-2 microglobulin. The variation coefficient is to the 15% (tolerance limit
derived from biological variation of this analyte is up to 15.5%). The determination of monoclonal immunoglobulins
concentration confirmed the known experience that it is impossible to consolidate the determination
because of many partial uncertain steps. Nevertheless the study showed clinical usability and analytical comparability
of the results from the single centers with the concentration of paraproteins over 20 g/l. Conclusion: The
determination of albumin is well standardized and the results from all laboratories are comparable. The determination
of beta-2 microglobulin after a methodical unification provides comparable results without any significant
differences. The determination of the monoclonal immunoglobulins concentration provided comparable
results especially in concentrations higher than 20 g/l. This determination is mostly questionable, but it is concerned
to monitor reactive changes by every laboratory, therefore the integration of the results has not been actual
so far.
Key words:
multiple myeloma, monoclonal immunoglobulin, albumin, beta-2 microglobulin, standardization
|